1-Year Results of Paclitaxel-Coated Balloons for Long Femoropopliteal Artery Disease
| Autor: | Alfredo Marchese, Fausto Castriota, Antonio Micari, Bruno Mario Cesana, Giuseppe Roscitano, Armando Liso, Chiara Grattoni, P. Russo, Giuseppe Vadalà, Alberto Cremonesi, Paolo Pantaleo |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Target lesion
medicine.medical_specialty Percutaneous Vascular disease business.industry medicine.medical_treatment Stent Femoral artery 030204 cardiovascular system & hematology medicine.disease Revascularization Popliteal artery Surgery 03 medical and health sciences 0302 clinical medicine medicine.artery Cardiovascular agent medicine 030212 general & internal medicine Radiology Cardiology and Cardiovascular Medicine business |
| Zdroj: | JACC: Cardiovascular Interventions. 9:950-956 |
| ISSN: | 1936-8798 |
| DOI: | 10.1016/j.jcin.2016.02.014 |
| Popis: | Objectives The aim of this study was to appraise 1-year outcomes after percutaneous treatment of long femoropopliteal artery disease using paclitaxel-coated balloons. Background Percutaneous transluminal angioplasty with paclitaxel-coated balloons for TransAtlantic Inter-Society Consensus types A and B femoropopliteal artery disease has provided favorable results. Methods Consecutive patients with Rutherford class 2 to 4 disease due to femoropopliteal lesions >15 cm long and with 4- to 7-mm reference vessel diameter were prospectively enrolled in a multicenter study. The primary study endpoint was primary patency at 12 months. Secondary endpoints included major adverse events (the composite of death, major target limb amputation, thrombosis at the target lesion site, or clinically driven non-target lesion target vessel revascularization), changes in Rutherford class, ankle-brachial index, and quality of life up to 24 months post-procedure. Results A total of 105 patients (mean age 68 ± 9 years, 81.9% men) treated with paclitaxel-coated balloons and provisional stenting were enrolled, and final procedural success was obtained in all. The mean treated lesion length was 251 ± 71 mm, including 63.4% moderate to severely calcified lesions and 49.5% total occlusions. The bailout stent rate was 10.9%. Follow-up after 12 months was obtained in 101 patients (96.2%), showing that primary patency was maintained in 84 (83.2%), and major adverse events had occurred in 7 (6.2%), with persistently significant clinical benefits in Rutherford class. Conclusions Paclitaxel-coated balloons are associated with favorable functional and clinical outcomes at 1 year in patients with long femoropopliteal artery disease requiring percutaneous revascularization. (Drug Eluting Balloon [DEB] and Long Lesions of Superficial Femoral Artery [SFA] Ischemic Vascular Disease [DEB-SFA-LONG]; NCT01658540). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|